Somatic hypermutation of the YAP oncogene in a human cutaneous melanoma

Zhang, X; Tang, JZ; Vergara, IA; Zhang, Y; Szeto, P; Yang, L; Mintoff, C; Colebatch, A; McIntosh, L; Mitchell, KA; Shaw, E; Rizos, H; Long, GV; Hayward, N; McArthur, GA; Papenfuss, AT; Harvey, KF; Shackleton, M

Author(s): Zhang, X; Tang, JZ; Vergara, IA; Zhang, Y; Szeto, P; Yang, L; Mintoff, C; Colebatch, A; McIntosh, L; Mitchell, KA; Shaw, E; Rizos, H; Long, GV; Hayward, N; McArthur, GA; Papenfuss, AT; Harvey, KF; Shackleton, M;
Details: Publication Year 2019-07,Volume 17,Issue #7,Page 1435-1449
Journal Title: Molecular Cancer Research
Publication Type: Journal Article
Abstract: Melanoma is usually driven by mutations in BRAF or NRAS that trigger hyperactivation of mitogen-activated protein kinase (MAPK) signalling. However, MAPK-targeted therapies are not sustainably effective in most patients. Accordingly, characterizing mechanisms that co-operatively drive melanoma progression is key to improving patient outcomes. One possible mechanism is the Hippo signalling pathway, which regulates cancer progression via its central oncoproteins YAP and TAZ, although is thought to be only rarely affected by direct mutation. As YAP hyperactivation occurs in uveal melanoma, we investigated this oncogene in cutaneous melanoma. YAP protein expression was elevated in most benign nevi and primary cutaneous melanomas but present at only very low levels in normal melanocytes. In patient-derived xenografts and melanoma cell lines, we observed variable reliance of cell viability on Hippo pathway signalling that was independent of TAZ activity and also of classical melanoma driver mutations such as BRAF and NRAS. Finally, in genotyping studies of melanoma, we observed the first ever hyperactivating YAP mutations in a human cancer, manifest as seven distinct missense point mutations that caused serine to alanine transpositions. Strikingly, these mutate four serine residues known to be targeted by the Hippo pathway and we show that they lead to hyperactivation of YAP. Implications: Our studies highlight the YAP oncoprotein as a potential therapeutic target in select sub-groups of melanoma patients, although successful treatment with anti-YAP therapies will depend on identification of biomarkers additional to YAP protein expression.
Publisher: AACR
Research Division(s): Bioinformatics
PubMed ID: 30833299
Publisher's Version: https://doi.org/10.1158/1541-7786.MCR-18-0407
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2019-03-13 11:54:01

Last Modified: 2020-05-06 08:40:38